Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter September 2015

 Entresto (en-TRESS-toh), a new drug for systolic heart failure. 

You'll hear lots of buzz about Entresto (en-TRESS-toh), a new drug for systolic heart failure.  
 It's the first "angiotensin receptor neprilysin inhibitor" (ARNI)...and combines valsartan with sacubitril (sah-KYOO-bih-tril).
   Sacubitril works by inhibiting the enzyme neprilysin. This increases sodium loss and vasodilation...and enhances ARB efficacy.
   This combo is MORE effective than an ACEI alone.  

For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE